Table 4. Hazard ratios for mortality according to AKI with or without Scr >132 mmol/l (N = 4,733).

	30 day mortality	90 day mortality
No of event (%)	1002(21.2%)	1569(33.2%)
No AKI	1[reference]	1[reference]
AKI stage 1	3.52(2.63, 4.72)	2.54(2.04, 3.18)
AKI stage 2	5.66(4.56, 7.03)	3.64(3.09, 4.3)
AKI stage 3	21.28(18.26, 24.78)	12.29(10.94, 13.81)

Model was adjusted for age, gender, comorbid disease(MI, PVD, CEVD, CHF, diabetes uncomplicated/complicated, cancer, COPD, DEMENTIA, AIDS/HIV, metastatic carcinoma, paraplegia and hemiplegia, peptic ulcer disease, connective tissue disease, and rheumatic disease), paracentesis and esophageal varices with bleeding during hospitalization, and baseline kidney function(baseline eGFR).Follow-up started from hospital admission date for all participants. AKI episodes were treated as a time-varying exposure.